Jazz bets on epilepsy again by acquiring Actio for $820M upfrontnews2026-08-10T13:45:18+00:00August 10th, 2026|Endpoints News|
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancernews2026-08-10T11:31:25+00:00August 10th, 2026|Endpoints News|
BioNTech vets get $25M seed funding for virtual cancer surveillance startupnews2026-08-10T11:00:22+00:00August 10th, 2026|Endpoints News|
Is China’s work ethic a ‘wake-up call’?; The megamerger that wasn’t; and morenews2026-08-08T10:00:08+00:00August 8th, 2026|Endpoints News|
BINSA legislation to limit biotech deals in China unveiled in Senatenews2026-08-07T16:35:22+00:00August 7th, 2026|Endpoints News|
FDA to hold adcomm for Grail cancer test that failed in large, randomized trialnews2026-08-07T16:08:57+00:00August 7th, 2026|Endpoints News|
BioMarin discontinues rare disease drug; CSL and Arcturus split upnews2026-08-07T15:08:24+00:00August 7th, 2026|Endpoints News|
China biotech will slow as it nears R&D frontier, Pfizer’s Baum predictsnews2026-08-07T15:00:01+00:00August 7th, 2026|Endpoints News|
Jennifer Taubert announces retirement from J&J; Takeda’s global TYK2 leader exitsnews2026-08-07T11:00:07+00:00August 7th, 2026|Endpoints News|
BlossomHill, Latigo cap four-IPO week with combined $496M haulnews2026-08-07T08:39:12+00:00August 7th, 2026|Endpoints News|
